Sociodemographic characteristics | Descriptive |
 Age (years), mean (SD) | 36.44 (12.83) |
 Sex, female, n (%) | 191 (90.95) |
 Marital status, n (%) | |
  Married | 148 (70.48) |
  Other marital status | 62 (29.52) |
 Education level, n (%) | |
  Primary (0–6 years) | 27 (12.86) |
  Secondary (7–12 years) | 78 (37.14) |
  Higher (>12 years) | 105 (50.00) |
 Employment, n (%) | |
  Employed | 105 (50.00) |
  Unemployed | 105 (50.00) |
Disease characteristic | Descriptive |
 Disease duration, n (%) | |
  <1 year | 12 (5.71) |
  1–5 year | 98 (46.67) |
   ≥ 5 year | 100 (47.62) |
 Comorbidities, n (%) | |
  0 | 75 (35.71) |
  1 | 75 (35.71) |
  2 | 33 (15.71) |
   ≥ 3 | 27 (12.86) |
 EQ-5D Index, mean (SD) | 0.72 (0.26) |
  SLEDAI-2 K | |
  0–4 | 98 (46.67) |
  5–9 | 50 (23.81) |
  10–14 | 41 (19.52) |
   ≥ 15 | 21 (10.00) |
 SLICC Index, mean (SD) | 0.87(1.26) |
Treatment characteristic | Descriptive |
 Types of pills prescribed daily, mean (SD) | 4.86 (2.20) |
 Use of GC, n (%) | 198 (94.29) |
 Number of immunomodulators&immunosuppressants, mean (SD) | 0.89 (0.70) |
 Use of NSAID, n (%) | 18 (8.57) |
 Use of biologic drugs, n (%) | 22 (10.47) |
 Daily dosing frequency, n (%) | |
  < once daily | 27 (12.86) |
  once daily | 46 (21.90) |
  Twice daily | 87 (41.43) |
  Thrice daily | 47 (22.38) |
  > Thrice daily | 3 (1.43) |
 Side effects, n (%) | |
  0 | 175(83.33) |
  1–2 | 28(13.33) |
   ≥ 3 | 7 (3.33) |
 CQR19, mean (SD) | 74.06 (8.93) |